NO2023048I1 - A composition comprising: cedazuridine or a pharmaceutically acceptable salt thereof, and decitabine - Google Patents
A composition comprising: cedazuridine or a pharmaceutically acceptable salt thereof, and decitabineInfo
- Publication number
- NO2023048I1 NO2023048I1 NO2023048C NO2023048C NO2023048I1 NO 2023048 I1 NO2023048 I1 NO 2023048I1 NO 2023048 C NO2023048 C NO 2023048C NO 2023048 C NO2023048 C NO 2023048C NO 2023048 I1 NO2023048 I1 NO 2023048I1
- Authority
- NO
- Norway
- Prior art keywords
- cedazuridine
- decitabine
- composition
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 title 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 title 1
- 229940063170 cedazuridine Drugs 0.000 title 1
- 229960003603 decitabine Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98039707P | 2007-10-16 | 2007-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO2023048I1 true NO2023048I1 (en) | 2023-12-21 |
Family
ID=40251685
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO2023048C NO2023048I1 (en) | 2007-10-16 | 2023-12-21 | A composition comprising: cedazuridine or a pharmaceutically acceptable salt thereof, and decitabine |
| NO2023047C NO2023047I1 (no) | 2007-10-16 | 2023-12-21 | Cedazuridine, or a pharmaceutically acceptable salt thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO2023047C NO2023047I1 (no) | 2007-10-16 | 2023-12-21 | Cedazuridine, or a pharmaceutically acceptable salt thereof |
Country Status (39)
| Country | Link |
|---|---|
| US (4) | US8268800B2 (no) |
| EP (2) | EP2447272B1 (no) |
| JP (2) | JP5496899B2 (no) |
| KR (1) | KR101543049B1 (no) |
| CN (1) | CN101827856B (no) |
| AT (1) | ATE548374T1 (no) |
| BR (1) | BRPI0818672B8 (no) |
| CA (1) | CA2702274C (no) |
| CO (1) | CO6270330A2 (no) |
| CR (1) | CR11427A (no) |
| CY (3) | CY1112781T1 (no) |
| DK (1) | DK2207786T3 (no) |
| EA (1) | EA018757B1 (no) |
| EC (1) | ECSP10010095A (no) |
| ES (2) | ES2384011T3 (no) |
| FI (2) | FIC20230040I1 (no) |
| FR (2) | FR23C1051I1 (no) |
| GT (1) | GT201000088A (no) |
| HK (1) | HK1146410A1 (no) |
| HR (1) | HRP20120419T1 (no) |
| HU (2) | HUS2300045I1 (no) |
| IL (1) | IL204732A (no) |
| JO (1) | JO2778B1 (no) |
| ME (1) | ME00997B (no) |
| MX (1) | MX2010004109A (no) |
| MY (1) | MY147970A (no) |
| NI (1) | NI201000055A (no) |
| NL (1) | NL301256I2 (no) |
| NO (2) | NO2023048I1 (no) |
| NZ (1) | NZ584229A (no) |
| PL (1) | PL2207786T3 (no) |
| PT (1) | PT2207786E (no) |
| RS (1) | RS52323B (no) |
| SA (1) | SA08290661B1 (no) |
| SI (1) | SI2207786T1 (no) |
| TW (1) | TWI445539B (no) |
| UA (1) | UA99476C2 (no) |
| WO (1) | WO2009052287A1 (no) |
| ZA (1) | ZA201002178B (no) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| JO2778B1 (en) * | 2007-10-16 | 2014-03-15 | ايساي انك | Certain vehicles, installations and methods |
| WO2009139888A1 (en) | 2008-05-15 | 2009-11-19 | Celgene Corporation | Oral formulations of cytidine analogs and methods of use thereof |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| US20100055047A1 (en) * | 2008-08-26 | 2010-03-04 | Yiyu Zou | Methods for treating bronchial premalignancy and lung cancer |
| CL2009002206A1 (es) * | 2008-12-23 | 2011-08-26 | Gilead Pharmasset Llc | Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales. |
| EP2417146B1 (en) * | 2009-04-06 | 2016-07-13 | Otsuka Pharmaceutical Co., Ltd. | (2'-deoxy-ribofuranosyl)-1,3,4,7-tetrahydro-(1,3)diazepin-2-one derivatives for treating cancer |
| AU2010234562B2 (en) * | 2009-04-06 | 2016-05-12 | Otsuka Pharmaceutical Co., Ltd. | Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer |
| US8609631B2 (en) | 2009-04-06 | 2013-12-17 | Eisai Inc. | Compositions and methods for treating cancer |
| JP5730854B2 (ja) * | 2009-04-06 | 2015-06-10 | 大塚製薬株式会社 | デシタビンとシチジンデアミナーゼ阻害剤との組合せ、およびがんの治療におけるその使用 |
| GB0907551D0 (en) | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
| TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| KR101715981B1 (ko) | 2010-03-31 | 2017-03-13 | 길리애드 파마셋 엘엘씨 | 뉴클레오사이드 포스포르아미데이트 |
| PL3290428T3 (pl) | 2010-03-31 | 2022-02-07 | Gilead Pharmasset Llc | Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu |
| US8841275B2 (en) | 2010-11-30 | 2014-09-23 | Gilead Pharmasset Llc | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections |
| DE202012013074U1 (de) | 2011-09-16 | 2014-10-29 | Gilead Pharmasset Lcc | Zusammensetzungen zur Behandlung von HCV |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| SI2950786T1 (sl) | 2013-01-31 | 2020-03-31 | Gilead Pharmasset Llc | Formulacija kombinacije dveh protivirusnih spojin |
| ES2900570T3 (es) | 2013-08-27 | 2022-03-17 | Gilead Pharmasset Llc | Formulación de combinación de dos compuestos antivirales |
| KR102272773B1 (ko) * | 2013-10-29 | 2021-07-02 | 오츠카 세이야쿠 가부시키가이샤 | 2'-데옥시-2',2'-디플루오로테트라하이드로우리딘의 합성 경로 |
| CN106659765B (zh) | 2014-04-04 | 2021-08-13 | 德玛医药 | 二脱水半乳糖醇及其类似物或衍生物用于治疗非小细胞肺癌和卵巢癌的用途 |
| SI3182996T1 (sl) | 2014-08-22 | 2023-04-28 | Celgene Corporation | Postopki zdravljenja multiplega mieloma z imunomodulatornimi spojinami v kombinaciji s protitelesi |
| EP3383406B1 (en) * | 2015-12-03 | 2021-10-20 | Epidestiny, Inc. | Compositions containing decitabine, 5-azacytidine and tetrahydrouridine and uses thereof |
| WO2017158396A1 (en) | 2016-03-16 | 2017-09-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Cytidine deaminase inhibitors for the treatment of pancreatic cancer |
| BR112020015745A2 (pt) | 2018-02-02 | 2020-12-08 | Maverix Oncology, Inc. | Conjugados de fármacos de moléculas pequenas de monofosfato de gemcitabina |
| US11224610B2 (en) * | 2018-09-19 | 2022-01-18 | Otsuka Pharmaceutical Co., Ltd. | Low dose combination CDA substrate drug/cedazuridine with extended administration |
| WO2020080912A1 (ko) * | 2018-10-19 | 2020-04-23 | 인터올리고 주식회사 | 치료 효능을 개선한 핵산 변형체 및 이를 포함하는 항암용 약학 조성물 |
| EP3868774A4 (en) * | 2018-10-19 | 2023-05-10 | Interoligo Corporation | MODIFIED NUCLEIC ACID WITH IMPROVED TREATMENT EFFICIENCY AND ANTI-CANCER PHARMACEUTICAL COMPOSITION THEREOF |
| KR20220078619A (ko) | 2019-10-08 | 2022-06-10 | 오츠카 세이야쿠 가부시키가이샤 | 고순도의 2'-데옥시-2',2'-디플루오로테트라히드로우리딘 및 그의 제조 방법 |
| WO2021173598A1 (en) * | 2020-02-25 | 2021-09-02 | Otsuka Pharmaceutical Co., Ltd. | Combination decitabine and cedazuridine solid oral dosage forms |
| MX2023011120A (es) * | 2021-03-26 | 2023-10-03 | Cleveland Clinic Found | Tratamiento de la infeccion por virus de arn con un inhibidor de citidina deaminasa. |
| WO2022254457A1 (en) * | 2021-05-29 | 2022-12-08 | Msn Laboratories Private Limited, R&D Center | An improved process for the preparation of (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl) oxolan-2-yl]-4-hydroxy-1,3-diazinan-2one and its intermediate compounds |
| AU2022370354A1 (en) | 2021-10-19 | 2024-05-30 | Akirabio, Inc. | Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers |
| WO2023076332A1 (en) * | 2021-11-01 | 2023-05-04 | St. John's University | Injectable liquid pharmaceutical compostion containing gemcitabine and a cytidine deaminase inhibitor |
| US20230271996A1 (en) * | 2021-12-25 | 2023-08-31 | Scinopharm Taiwan, Ltd. | Process for preparing cedazuridine |
| WO2024047394A1 (en) | 2022-08-31 | 2024-03-07 | Otsuka Pharmaceutical Co., Ltd. | Combination therapies for treatment of t-cell lymphomas with tolinapant, cedazuridine and decitabine |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4017606A (en) | 1973-10-04 | 1977-04-12 | The Upjohn Company | Organic compounds and process |
| US4210638A (en) * | 1978-03-17 | 1980-07-01 | Pcr, Inc. | Antiviral composition and method of treating virus diseases |
| US4275057A (en) | 1980-01-28 | 1981-06-23 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Seven-membered ring compounds as inhibitors of cytidine deaminase |
| US4526988A (en) | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
| JPS61500224A (ja) | 1983-10-26 | 1986-02-06 | グリ−ル、シエルダン ビ− | 腫瘍性組織を放射線に対して増感する医薬組成物 |
| DE3587500T2 (de) | 1984-12-04 | 1993-12-16 | Lilly Co Eli | Tumorbehandlung bei Säugetieren. |
| US4965374A (en) | 1987-08-28 | 1990-10-23 | Eli Lilly And Company | Process for and intermediates of 2',2'-difluoronucleosides |
| US5223608A (en) | 1987-08-28 | 1993-06-29 | Eli Lilly And Company | Process for and intermediates of 2',2'-difluoronucleosides |
| US5968914A (en) | 1987-10-28 | 1999-10-19 | Pro-Neuron, Inc. | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
| WO1992018517A1 (en) | 1991-04-17 | 1992-10-29 | Yale University | Method of treating or preventing hepatitis b virus |
| EP0543976A4 (en) | 1991-04-23 | 1993-11-10 | Oglevee, Ltd. | In vitro leaf petiole multiplication of pelargoniums |
| FR2682112B1 (fr) | 1991-10-08 | 1993-12-10 | Commissariat A Energie Atomique | Procede de synthese d'acide ribonucleique (arn) utilisant un nouveau reactif de deprotection. |
| US5821357A (en) | 1992-06-22 | 1998-10-13 | Eli Lilly And Company | Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides |
| US5594124A (en) | 1992-06-22 | 1997-01-14 | Eli Lilly And Company | Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof |
| US5426183A (en) | 1992-06-22 | 1995-06-20 | Eli Lilly And Company | Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
| US5371210A (en) | 1992-06-22 | 1994-12-06 | Eli Lilly And Company | Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
| US5606048A (en) | 1992-06-22 | 1997-02-25 | Eli Lilly And Company | Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
| DE69403588T2 (de) | 1993-02-23 | 1998-01-22 | Hope City | 4-ethoxy-5-fluor-2'-deoxyuridine |
| AU6081294A (en) * | 1993-05-14 | 1994-12-12 | Pro-Neuron, Inc. | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
| GB9311252D0 (en) | 1993-06-01 | 1993-07-21 | Hafslund Nycomed As | Cell growth regualtors |
| US5637688A (en) | 1994-12-13 | 1997-06-10 | Eli Lilly And Company | Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride |
| US5521294A (en) | 1995-01-18 | 1996-05-28 | Eli Lilly And Company | 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides |
| WO1996026743A1 (en) * | 1995-03-01 | 1996-09-06 | Human Gene Therapy Research Institute | Radiation enhanced gene therapy for treatment of tumors |
| US6001994A (en) | 1995-12-13 | 1999-12-14 | Eli Lilly And Company | Process for making gemcitabine hydrochloride |
| US5760208A (en) | 1996-08-14 | 1998-06-02 | The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations | Process to prepare pyrimidine nucleosides |
| ATE339960T1 (de) | 1999-03-01 | 2006-10-15 | Halogenetics Inc | Verwendung von zusammensetzungen enthaltend cldc als strahlungssensibilisatoren in der behandlung von neoplastischen erkrankungen |
| US6933287B1 (en) | 1999-03-01 | 2005-08-23 | Sheldon B. Greer | Dramatic simplification of a method to treat neoplastic disease by radiation |
| WO2001013789A1 (en) | 1999-08-26 | 2001-03-01 | Aortech International Plc | Improvements relating to catheter positioning |
| US6462191B1 (en) | 2000-07-13 | 2002-10-08 | Air Products And Chemicals, Inc. | Synthesis of 2-deoxy-2-fluoro-arabinose derivatives |
| US7125983B2 (en) | 2000-11-29 | 2006-10-24 | Mitsui Chemicals, Inc. | L-nucleic acid derivatives and process for the synthesis thereof |
| ATE290882T1 (de) | 2001-01-16 | 2005-04-15 | Glaxo Group Ltd | Pharmazeutische mischung gegen krebs, die ein 4- chinazolinamin in kombination mit paclitaxel, carboplatin or vinorelbine enthält |
| EP1387850A2 (en) | 2001-05-18 | 2004-02-11 | Rakesh Kumar | Antiviral nucleosides |
| US8207142B2 (en) * | 2001-07-31 | 2012-06-26 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Inhibitor of DNA methylation |
| JP2005522443A (ja) | 2002-02-14 | 2005-07-28 | フアーマセツト・リミテツド | 改変フッ素化ヌクレオシド類似体 |
| US6982253B2 (en) | 2002-06-05 | 2006-01-03 | Supergen, Inc. | Liquid formulation of decitabine and use of the same |
| CA2499036A1 (en) | 2002-09-24 | 2004-04-08 | Koronis Pharmaceuticals, Incorporated | 1,3,5-triazines for treatment of viral diseases |
| US7265096B2 (en) | 2002-11-04 | 2007-09-04 | Xenoport, Inc. | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof |
| US8158770B2 (en) | 2004-05-06 | 2012-04-17 | University Of Rochester | Content dependent inhibitors of cytidine deaminases and uses thereof |
| US20060014949A1 (en) | 2004-07-13 | 2006-01-19 | Supergen Inc. | Compositions and formulations of decitabine polymorphs and methods of use thereof |
| TW200606159A (en) | 2004-07-30 | 2006-02-16 | Pharmaessentia Corp | Stereoselective synthesis of β-nucleosides |
| JP2007522151A (ja) | 2004-12-08 | 2007-08-09 | シコール インコーポレイティド | ジフルオロヌクレオシド及びその調製方法 |
| WO2008085611A2 (en) | 2006-11-27 | 2008-07-17 | University Of Miami | Designer theraphy of pancreatic tumors |
| WO2009021551A1 (en) | 2007-08-13 | 2009-02-19 | Universite De La Mediterranee | A method for assessing the risk of toxicity in a chemotherapy |
| JO2778B1 (en) | 2007-10-16 | 2014-03-15 | ايساي انك | Certain vehicles, installations and methods |
| WO2010047698A1 (en) | 2008-10-22 | 2010-04-29 | University Of Alabama At Birmingham | Activation-induced cytidine deaminase inhibitor suppression of autoimmune diseases |
| EP2417146B1 (en) | 2009-04-06 | 2016-07-13 | Otsuka Pharmaceutical Co., Ltd. | (2'-deoxy-ribofuranosyl)-1,3,4,7-tetrahydro-(1,3)diazepin-2-one derivatives for treating cancer |
| JP5730854B2 (ja) | 2009-04-06 | 2015-06-10 | 大塚製薬株式会社 | デシタビンとシチジンデアミナーゼ阻害剤との組合せ、およびがんの治療におけるその使用 |
| AU2010234562B2 (en) | 2009-04-06 | 2016-05-12 | Otsuka Pharmaceutical Co., Ltd. | Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer |
| US8609631B2 (en) | 2009-04-06 | 2013-12-17 | Eisai Inc. | Compositions and methods for treating cancer |
-
2008
- 2008-10-14 JO JO2008459A patent/JO2778B1/en active
- 2008-10-15 TW TW097139594A patent/TWI445539B/zh active
- 2008-10-16 RS RS20120232A patent/RS52323B/en unknown
- 2008-10-16 ES ES08840633T patent/ES2384011T3/es active Active
- 2008-10-16 UA UAA201003977A patent/UA99476C2/ru unknown
- 2008-10-16 EP EP12151552.2A patent/EP2447272B1/en active Active
- 2008-10-16 AT AT08840633T patent/ATE548374T1/de active
- 2008-10-16 KR KR1020107010621A patent/KR101543049B1/ko active IP Right Grant
- 2008-10-16 NZ NZ584229A patent/NZ584229A/en unknown
- 2008-10-16 PL PL08840633T patent/PL2207786T3/pl unknown
- 2008-10-16 WO PCT/US2008/080163 patent/WO2009052287A1/en active Application Filing
- 2008-10-16 ME MEP-2010-68A patent/ME00997B/me unknown
- 2008-10-16 CA CA2702274A patent/CA2702274C/en active Active
- 2008-10-16 SI SI200830624T patent/SI2207786T1/sl unknown
- 2008-10-16 PT PT08840633T patent/PT2207786E/pt unknown
- 2008-10-16 MX MX2010004109A patent/MX2010004109A/es active IP Right Grant
- 2008-10-16 EP EP08840633A patent/EP2207786B1/en active Active
- 2008-10-16 CN CN2008801117195A patent/CN101827856B/zh active Active
- 2008-10-16 DK DK08840633.5T patent/DK2207786T3/da active
- 2008-10-16 MY MYPI2010001528A patent/MY147970A/en unknown
- 2008-10-16 EA EA201000642A patent/EA018757B1/ru unknown
- 2008-10-16 US US12/252,961 patent/US8268800B2/en active Active
- 2008-10-16 JP JP2010530110A patent/JP5496899B2/ja active Active
- 2008-10-16 ES ES12151552.2T patent/ES2616566T3/es active Active
- 2008-10-16 BR BRPI0818672A patent/BRPI0818672B8/pt active IP Right Grant
- 2008-10-18 SA SA08290661A patent/SA08290661B1/ar unknown
-
2010
- 2010-01-26 ZA ZA2010/02178A patent/ZA201002178B/en unknown
- 2010-03-25 IL IL204732A patent/IL204732A/en active IP Right Grant
- 2010-04-09 EC EC2010010095A patent/ECSP10010095A/es unknown
- 2010-04-12 GT GT201000088A patent/GT201000088A/es unknown
- 2010-04-14 NI NI201000055A patent/NI201000055A/es unknown
- 2010-05-12 CR CR11427A patent/CR11427A/es unknown
- 2010-05-13 CO CO10057462A patent/CO6270330A2/es active IP Right Grant
-
2011
- 2011-01-20 HK HK11100565.2A patent/HK1146410A1/xx unknown
-
2012
- 2012-05-16 HR HRP20120419AT patent/HRP20120419T1/hr unknown
- 2012-05-24 CY CY20121100467T patent/CY1112781T1/el unknown
- 2012-07-24 US US13/556,404 patent/US8618075B2/en active Active
-
2013
- 2013-11-25 US US14/088,465 patent/US8951987B2/en active Active
-
2014
- 2014-03-05 JP JP2014043175A patent/JP5859588B2/ja active Active
- 2014-12-29 US US14/584,437 patent/US9567363B2/en active Active
-
2023
- 2023-12-21 HU HUS2300045C patent/HUS2300045I1/hu unknown
- 2023-12-21 NO NO2023048C patent/NO2023048I1/no unknown
- 2023-12-21 HU HUS2300044C patent/HUS2300044I1/hu unknown
- 2023-12-21 NO NO2023047C patent/NO2023047I1/no unknown
- 2023-12-22 CY CY2023029C patent/CY2023029I1/el unknown
- 2023-12-22 FI FIC20230040C patent/FIC20230040I1/fi unknown
- 2023-12-22 FI FIC20230039C patent/FIC20230039I1/fi unknown
- 2023-12-22 CY CY2023028C patent/CY2023028I1/el unknown
- 2023-12-26 FR FR23C1051C patent/FR23C1051I1/fr active Active
- 2023-12-26 FR FR23C1052C patent/FR23C1052I1/fr active Active
- 2023-12-27 NL NL301256C patent/NL301256I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO2023048I1 (en) | A composition comprising: cedazuridine or a pharmaceutically acceptable salt thereof, and decitabine | |
| HUS000509I2 (hu) | Abemaciklib vagy egy gyógyászatilag elfogadható sója | |
| EP2124550A4 (en) | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND THEIR USE | |
| SI2217578T1 (sl) | (1,2,4)triazolo(1,5-a)piridinske in (1,2,4)triazolo(1,5-c)pirimidinske spojine in njihova uporaba | |
| IL205071A (en) | Its azulcarboxamide or salt compound, a pharmaceutical product containing it and its uses | |
| EP2153838A4 (en) | ANTI-NOROVIRUS AGENT AND COMPOSITION COMPRISING SAME | |
| ZA201000185B (en) | 17beta-cyano-18a-homo-19-nor-androst-4-ene derivative,use thereof and medicaments containing said derivative | |
| EP2063725A4 (en) | HELMET | |
| AU313806S (en) | Helmet | |
| GB0702915D0 (en) | Insecticidal composition | |
| HK1131140A1 (en) | Substituted prolinamides, and the use thereof | |
| GB2440664B (en) | Insecticidal composition | |
| IL193882A0 (en) | Pesticidal composition | |
| EP2208732A4 (en) | DEHYDROXYLATED VANCOMYCIN, PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
| GB0625783D0 (en) | Medicament | |
| GB0621562D0 (en) | Network administration | |
| IL193384A0 (en) | Substituted prolinamides, their preparation and their use as pharmaceuticals | |
| GB0819432D0 (en) | Compound, composition and use | |
| ZA201000187B (en) | 17b-cyano-19-nor-androst-4-ene derivative,use thereof and medicaments containing said derivative | |
| EP2192122A4 (en) | Dithiolopyrrolone compounds and their preparation and use | |
| ZA200807638B (en) | Pesticidal composition | |
| ZA200807639B (en) | Pesticidal composition | |
| GB0608991D0 (en) | Descender | |
| GB0615064D0 (en) | Medicament | |
| ZA201000186B (en) | 17b-cyano-19-androst-4-ene derivative,use thereof and medicaments containing said derivative |